230 related articles for article (PubMed ID: 199393)
1. Plasma concentration of pyridostigmine and effects in myastenia gravis.
Chan K; Calvey TN
Clin Pharmacol Ther; 1977 Nov; 22(5 Pt 1):596-601. PubMed ID: 199393
[TBL] [Abstract][Full Text] [Related]
2. Plasma concentration and pharmacological effects of pyridostigmine in patients with myasthenia gravis [proceedings].
Calvey TN; Chan K
Br J Clin Pharmacol; 1977 Jun; 4(3):404P. PubMed ID: 197984
[No Abstract] [Full Text] [Related]
3. Quantitative correlation between plasma pyridostigmine levels and neuromuscular function in myasthenia gravis.
Milner-Brown HS; Mellenthin M; Sharma ML; Miller RG
Neurology; 1987 May; 37(5):800-3. PubMed ID: 3574680
[TBL] [Abstract][Full Text] [Related]
4. Neuromuscular function and plasma drug levels in pyridostigmine treatment of myasthenia gravis.
Breyer-Pfaff U; Schmezer A; Maier U; Brinkmann A; Schumm F
J Neurol Neurosurg Psychiatry; 1990 Jun; 53(6):502-6. PubMed ID: 2166138
[TBL] [Abstract][Full Text] [Related]
5. Preanesthetic train-of-four fade predicts the atracurium requirement of myasthenia gravis patients.
Mann R; Blobner M; Jelen-Esselborn S; Busley R; Werner C
Anesthesiology; 2000 Aug; 93(2):346-50. PubMed ID: 10910480
[TBL] [Abstract][Full Text] [Related]
6. [Serum levels of pyridostigmine in myasthenia gravis: methods and clinical significance].
Schumm F; Gaertner HJ; Wiatr G; Dichgans J
Fortschr Neurol Psychiatr; 1985 Jun; 53(6):201-11. PubMed ID: 2991094
[TBL] [Abstract][Full Text] [Related]
7. Plasma pyridostigmine levels in patients with myasthenia gravis.
Calvey TN; Chan K
Clin Pharmacol Ther; 1977 Feb; 21(2):187-93. PubMed ID: 837637
[TBL] [Abstract][Full Text] [Related]
8. The relationship of plasma levels of pyridostigmine to clinical effect in patients with myasthenia gravis.
Davison SC; Hyman NM; Dehghan A; Chan K
J Neurol Neurosurg Psychiatry; 1981 Dec; 44(12):1141-5. PubMed ID: 7334410
[TBL] [Abstract][Full Text] [Related]
9. Plasma pyridostigmine levels in myasthenia gravis.
White MC; De Silva P; Havard CW
Neurology; 1981 Feb; 31(2):145-50. PubMed ID: 7193298
[TBL] [Abstract][Full Text] [Related]
10. Vecuronium block in the myasthenic patient. Influence of anticholinesterase therapy.
Baraka A; Taha S; Yazbeck V; Rizkallah P
Anaesthesia; 1993 Jul; 48(7):588-90. PubMed ID: 8102223
[TBL] [Abstract][Full Text] [Related]
11. Pseudo plus-minus lid syndrome.
Bandini F
Arch Neurol; 2009 May; 66(5):668-9. PubMed ID: 19433671
[No Abstract] [Full Text] [Related]
12. Pyridostigmine levels in myasthenia gravis.
Kornfeld P; Mittag T; Genkins G; Papatestas AE; Horowitz SH
Neurology; 1977 Nov; 27(11):1099. PubMed ID: 563008
[No Abstract] [Full Text] [Related]
13. Improvement in neuromuscular transmission in myasthenia gravis by 3,4-diaminopyridine.
Lundh H; Nilsson O; Rosén I
Eur Arch Psychiatry Neurol Sci; 1985; 234(6):374-7. PubMed ID: 2992990
[TBL] [Abstract][Full Text] [Related]
14. Myasthenia congenita: electromyographic findings.
Gath I; Kayan A; Leegaard J; Sjaastad O
Acta Neurol Scand; 1970; 46(3):323-30. PubMed ID: 5505974
[No Abstract] [Full Text] [Related]
15. Determination of erythrocyte-bound acetylcholinesterase activity for monitoring pyridostigmine therapy in myasthenia gravis.
Henze T; Nenner M; Michaelis HC
J Neurol; 1991 Jul; 238(4):225-9. PubMed ID: 1895153
[TBL] [Abstract][Full Text] [Related]
16. Mivacurium chloride and myasthenia gravis.
Seigne RD; Scott RP
Br J Anaesth; 1994 Apr; 72(4):468-9. PubMed ID: 8155454
[TBL] [Abstract][Full Text] [Related]
17. Steady state kinetics of pyridostigmine in myasthenia gravis.
Sørensen PS; Flachs H; Friis ML; Hvidberg EF; Paulson OB
Neurology; 1984 Aug; 34(8):1020-4. PubMed ID: 6540381
[TBL] [Abstract][Full Text] [Related]
18. Suxamethonium block in the myasthenic patient. Correlation with plasma cholinesterase.
Baraka A
Anaesthesia; 1992 Mar; 47(3):217-9. PubMed ID: 1314525
[TBL] [Abstract][Full Text] [Related]
19. β2-Adrenergic receptor agonists ameliorate the adverse effect of long-term pyridostigmine on neuromuscular junction structure.
Vanhaesebrouck AE; Webster R; Maxwell S; Rodriguez Cruz PM; Cossins J; Wickens J; Liu WW; Cetin H; Cheung J; Ramjattan H; Palace J; Beeson D
Brain; 2019 Dec; 142(12):3713-3727. PubMed ID: 31633155
[TBL] [Abstract][Full Text] [Related]
20. Clinical pharmacology of pyridostigmine and neostigmine in patients with myasthenia gravis.
Aquilonius SM; Eckernäs SA; Hartvig P; Lindström B; Osterman PO; Stålberg E
J Neurol Neurosurg Psychiatry; 1983 Oct; 46(10):929-35. PubMed ID: 6644317
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
